| Pharmaceutical Information |
| Drug Name |
Telotristat ethyl |
| Drug ID |
BADD_D02503 |
| Description |
Telotristat only approved oral therapy for carcinoid syndrome diarrhea. Telotristat was approved by the FDA in March, 2017 as Xermelo. |
| Indications and Usage |
As a serotonin synthesis inhibitor, telotristat etiprate, has the potential to reduce serotonin levels and address the key elements of carcinoid syndrome. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB12095
|
| KEGG ID |
D09974
|
| MeSH ID |
C000621725
|
| PubChem ID |
25181577
|
| TTD Drug ID |
D0RE6T
|
| NDC Product Code |
70183-125; 11014-0462; 70720-125 |
| UNII |
8G388563M7
|
| Synonyms |
telotristat ethyl | Xermelo | LX1032 |
|
| Chemical Information |
| Molecular Formula |
C27H26ClF3N6O3 |
| CAS Registry Number |
1033805-22-9 |
| SMILES |
CCOC(=O)C(CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)OC(C3=C(C=C(C=C3)Cl)N4C=CC(=N4)C)C(F)(F)
F)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
